Thermo Fisher Scientific Inc. $TMO Shares Acquired by Tailwinds Wealth LLC

Tailwinds Wealth LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 146.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,762 shares of the medical research company’s stock after acquiring an additional 1,047 shares during the period. Tailwinds Wealth LLC’s holdings in Thermo Fisher Scientific were worth $883,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. SteelPeak Wealth LLC increased its stake in Thermo Fisher Scientific by 10.0% during the second quarter. SteelPeak Wealth LLC now owns 823 shares of the medical research company’s stock worth $413,000 after purchasing an additional 75 shares during the period. DAVENPORT & Co LLC grew its holdings in shares of Thermo Fisher Scientific by 8.3% in the second quarter. DAVENPORT & Co LLC now owns 5,851 shares of the medical research company’s stock valued at $2,933,000 after purchasing an additional 447 shares in the last quarter. Northside Capital Management LLC increased its stake in Thermo Fisher Scientific by 41.0% during the 2nd quarter. Northside Capital Management LLC now owns 32,741 shares of the medical research company’s stock worth $16,415,000 after buying an additional 9,519 shares during the period. Annex Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 12.6% during the 2nd quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company’s stock worth $12,361,000 after buying an additional 2,756 shares in the last quarter. Finally, Hudson Value Partners LLC boosted its position in Thermo Fisher Scientific by 24.9% in the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock valued at $8,349,000 after buying an additional 3,317 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 26,553 shares of company stock valued at $15,343,589. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $603.20 on Thursday. The company has a market cap of $223.03 billion, a P/E ratio of 32.45, a PEG ratio of 2.46 and a beta of 0.85. The firm has a fifty day moving average price of $524.79 and a 200 day moving average price of $509.23. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Jefferies Financial Group restated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Royal Bank Of Canada boosted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.